Acadian Asset Management LLC Makes New $93,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Acadian Asset Management LLC acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 8,357 shares of the biotechnology company’s stock, valued at approximately $93,000.

Several other large investors have also modified their holdings of ADMA. Assenagon Asset Management S.A. increased its position in ADMA Biologics by 1.1% during the second quarter. Assenagon Asset Management S.A. now owns 3,382,174 shares of the biotechnology company’s stock worth $37,813,000 after purchasing an additional 35,707 shares during the last quarter. Mesirow Institutional Investment Management Inc. acquired a new stake in shares of ADMA Biologics during the 1st quarter worth $17,221,000. Charles Schwab Investment Management Inc. raised its position in shares of ADMA Biologics by 1.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock worth $7,398,000 after buying an additional 27,357 shares during the period. Russell Investments Group Ltd. boosted its holdings in ADMA Biologics by 90.7% in the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after acquiring an additional 556,175 shares during the last quarter. Finally, Castleark Management LLC purchased a new stake in ADMA Biologics during the first quarter valued at about $5,400,000. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ADMA has been the topic of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a report on Friday. HC Wainwright raised their price target on shares of ADMA Biologics from $10.00 to $18.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Mizuho boosted their price objective on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Price Performance

Shares of NASDAQ ADMA opened at $19.98 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80. ADMA Biologics, Inc. has a 1-year low of $3.06 and a 1-year high of $20.16. The company has a market capitalization of $4.63 billion, a price-to-earnings ratio of -999.00 and a beta of 0.61. The business has a 50-day moving average of $15.77 and a 200-day moving average of $10.96.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analysts’ expectations of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s quarterly revenue was up 78.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) EPS. On average, equities analysts anticipate that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the business’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now owns 241,441 shares in the company, valued at approximately $4,408,712.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Jerrold B. Grossman sold 136,861 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $17.27, for a total transaction of $2,363,589.47. Following the completion of the transaction, the director now directly owns 467,305 shares in the company, valued at approximately $8,070,357.35. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the sale, the director now owns 241,441 shares of the company’s stock, valued at approximately $4,408,712.66. The disclosure for this sale can be found here. In the last three months, insiders sold 466,900 shares of company stock valued at $8,224,121. Corporate insiders own 3.70% of the company’s stock.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.